DISCOVER NOW NoNO Inc. is on the brink of achieving one of the most ambitious goals in 21st century medicine: protecting the brain against stroke. Our scientists and physicians have been at the forefront of stroke science for two decades with an unrelenting commitment to improving life after stroke. Today, we are industry leaders changing the paradigm of stroke therapy.
NEXT The Breakthrough Nerinetide, NoNO’s lead compound for people experiencing an ischemic stroke, currently completing its global Phase 3 program in people not previously treated with a clot dissolving drug. NEXT The Expansion StrokePen, with NoNO42 in Phase 1, for use alongside clot dissolving drugs for all people experiencing ischemic stroke. The Future NoNO-SC, administered subcutaneously with rapid onset and long action to enable the treatment of subacute and chronic neurological conditions outside of medical settings by anyone – anywhere. LEARN MORE